Juan Manuel Millán-Alanís

Juan Manuel Millán-Alanís

Auto-generated profile, based on publicly available information

Juan Manuel Millán-Alanís

Plataforma INVEST Medicina UANL KER Unit Mayo Clinic (KER Unit Mexico), Universidad Autónoma de Nuevo León, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Pharmacological Research
Verified
Journal Article
Closed access
ASAdriana Sánchez-García
Adriana Sánchez-García
MSMario Simental-Mendía
Mario Simental-Mendía
JMJuan Manuel Millán-Alanís
Juan Manuel Millán-Alanís
LSLuis E. Simental-Mendía
Luis E. Simental-Mendía

1 December 2019 in Orthopaedic Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
FVFélix Vilchez-Cavazos
Félix Vilchez-Cavazos
JMJuan Manuel Millán-Alanís
Juan Manuel Millán-Alanís
JBJaime Blázquez-Saldaña
Jaime Blázquez-Saldaña
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
VPVíctor Manuel Peña-Martínez
Víctor Manuel Peña-Martínez
MSMario Simental-Mendía
Mario Simental-Mendía
Background: Reports have concluded that platelet-rich plasma (PRP) is an effective and safe biological approach in the treatment of knee osteoarthritis (OA). However, no consensus has been established regarding the number of injections required to observe a therapeutic effect. Purpose: To compare the clinical effectiveness reported in randomized controlled trials (RCTs) of single versus multiple PRP injections in the treatment of knee OA. Study Design: Systematic review; Level of evidence, 1. Methods: A comprehensive search was conducted for RCTs published between 1970 and 2019 that compared the effect of single versus multiple PRP injections on pain and functionality in patients with knee OA. Searched databases included MEDLINE, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. A data extraction form was designed to obtain bibliographic information of the study as well as patient, intervention, comparison, and outcomes of interest data. A random-effects model was used to pool quantitative data from the primary outcomes. Results: We included 5 clinical trials with a low-moderate risk of bias that reported data for 301 patients. Meta-analysis showed that, at 6 months after the intervention, single and multiple (double or triple) injections had similar pain improvement, with no significant differences (standardized mean difference [SMD], 0.61 [95% CI, −1.09 to 2.31]; I 2 = 97%; P = .48). A significant improvement in knee functionality was observed in favor of multiple injections (SMD, 2.29 [95% CI, 0.45-4.12]; I 2 = 97%; P = .01). Subanalysis showed that the significant improvement was only evident for the results of single versus triple injections (SMD, 3.12 [95% CI, 0.64-5.60]; I 2 = 97%; P = .01). Conclusion: According to our results, a single injection was as effective as multiple PRP injections in pain improvement; however, multiple injections seemed more effective in joint functionality than a single injection at 6 months. We consider that the available evidence is still insufficient, and future research on this specific topic is needed to confirm our results.

10 November 2021 in Thyroid®
Verified
Journal Article
Closed access
JMJuan Manuel Millan-Alanis
Juan Manuel Millan-Alanis
JGJosé Gerardo González-González
José Gerardo González-González
AFAndrea Flores-Rodríguez
Andrea Flores-Rodríguez
NONaykky M Singh Ospina
Naykky M Singh Ospina
SMSpyridoula Maraka
Spyridoula Maraka
RRRené Rodríguez-Gutiérrez
René Rodríguez-Gutiérrez
Background: Combined therapy with levothyroxine (LT4)/L-triiodothyronine (LT3) has garnered attention among clinicians and patients as a potential treatment alternative to LT4 monotherapy. The objective of this study was to compare the benefits and harms of LT4/LT3 combined therapy and LT4 monotherapy for patients with hypothyroidism. Methods: A systematic search in MEDLINE, Scopus, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials was performed by a librarian from inception date until September 2020. Randomized clinical trials and quasiexperimental studies comparing combined therapy (LT4/LT3) versus monotherapy (LT4) for adult patients with hypothyroidism were considered for inclusion. Independent data extraction was performed by paired reviewers. A meta-analysis comparing standardized mean differences of the effect of each therapy was performed on clinical outcomes and patient preferences. Proportions of adverse events and reactions were assessed narratively. Results: A total of 1398 references were retrieved, from which 18 fulfilled the inclusion criteria. Results supported by evidence at low-to-moderate certainty evidence did not display a difference in treatment effect between therapies on clinical status, quality of life, psychological distress, depressive symptoms, and fatigue; all measured with standardized questionnaires. Furthermore, meta-analysis of patient preferences revealed higher proportions of choice for combined therapy (43%) when compared with monotherapy (23%) or having no preference (30%). When evaluating treatment adverse events or adverse reactions, similar proportions were observed between treatment groups; meta-analysis was not possible. Conclusions: The available evidence at low-to-moderate certainty demonstrates that there is no difference in clinical outcomes between LT4/LT3 combined therapy and LT4 monotherapy for treating hypothyroidism in adults, except for a higher proportion of patient preferring combined therapy. Adverse events and reactions appear to be similar across both groups, however, this observation is only narrative. These results could inform shared decision-making conversations between patients with hypothyroidism and their clinicians. PROSPERO Registration ID: CRD42020202658.

10 June 2021 in Archives of Women's Mental Health
Verified
Journal Article
Closed access
PDF file
JMJuan Manuel Millan-Alanis
Juan Manuel Millan-Alanis
FCFarid Carranza-Navarro
Farid Carranza-Navarro
HLHumberto de León-Gutiérrez
Humberto de León-Gutiérrez
PLPaloma C. Leyva-Camacho
Paloma C. Leyva-Camacho
AGAndrea Fernanda Guerrero-Medrano
Andrea Fernanda Guerrero-Medrano
ESErasmo Saucedo-Uribe
Erasmo Saucedo-Uribe

11 February 2020 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
CACarlos Alberto Acosta-Olivo
Carlos Alberto Acosta-Olivo
JMJuan Manuel Millán-Alanís
Juan Manuel Millán-Alanís
LSLuis Ernesto Simental-Mendía
Luis Ernesto Simental-Mendía
NÁNeri Álvarez-Villalobos
Neri Álvarez-Villalobos
FVFélix Vilchez-Cavazos
Félix Vilchez-Cavazos
MSMario Simental-Mendía
Mario Simental-Mendía
Background: Lateral epicondylitis, or tennis elbow, is a painful degenerative disorder that commonly occurs in adults between 40 and 60 years of age. Normal saline (NS) injections have been used as placebo through a large number of randomized controlled trials (RCTs) focused on the treatment of lateral epicondylitis. Purpose: This meta-analysis of RCTs aimed to assess the therapeutic effect of NS injections on lateral epicondylitis symptoms and compare results with established minimal clinically important difference criteria. Study Design: Systematic review and meta-analysis. Methods: MEDLINE, Embase, Web of Science, and Scopus databases were searched for clinical trials reporting pain and joint function with the visual analog scale, Patient-Rated Tennis Elbow Evaluation, and Disabilities of the Arm, Shoulder and Hand in patients with lateral epicondylitis. The meta-analysis was conducted with a random effects model and generic inverse variance method. Heterogeneity was tested with the I 2 statistic index. Results: A total of 15 RCTs included in this meta-analysis revealed a significant improvement in pain (mean difference, 3.61 cm [95% CI, 2.29-4.92 cm]; P < .00001; I 2 = 88%; visual analog scale) and function (mean difference, 25.65 [95% CI, 13.30-37.99]; P < .0001; I 2 = 82%; Patient-Rated Tennis Elbow Evaluation / Disabilities of the Arm, Shoulder and Hand) after NS injection (≥6 months). Conclusion: NS injections yielded a statistically significant and clinically meaningful improvement in pain and functional outcomes in patients with lateral epicondylitis. New research should focus on better methods to diminish the potential confounders that could lead to this effect because NS injections could mask the real effect of an active therapeutic intervention in RCT. Registration: CRD42019127547 (PROSPERO).

21 April 2022 in Primary Care Diabetes
Verified
Journal Article
Closed access
GGGerardo González-Saldivar
Gerardo González-Saldivar
JMJuan Manuel Millan-Alanis
Juan Manuel Millan-Alanis
JGJosé Gerardo González-González
José Gerardo González-González
RSRaymundo A. Sánchez-Gómez
Raymundo A. Sánchez-Gómez
JOJavier Obeso-Fernández
Javier Obeso-Fernández
RRRené Rodríguez-Gutiérrez
René Rodríguez-Gutiérrez